Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (1), 306

The ReThink Study: A 3-arm Parallel Randomized Trial of Cognitive Bias Modification, With and Without Adherence Promotion, for Adolescent Anxiety Disorder: Trial Design and Protocol

Affiliations

The ReThink Study: A 3-arm Parallel Randomized Trial of Cognitive Bias Modification, With and Without Adherence Promotion, for Adolescent Anxiety Disorder: Trial Design and Protocol

Shelley Reetz et al. BMC Psychiatry.

Abstract

Background: Anxiety disorders are the most common mental health problem among youth, contribute to reduced quality of daily life, and are associated with high rates of comorbidity. However, treatment rates for anxiety are very low, causing a sizeable treatment gap. There is an immediate need to identify treatment interventions that are effective, affordable, and can be delivered easily to the youth population. Cognitive Bias Modification (CBM) is one potentially effective intervention that could reach youth on a large scale, especially when self-administered at home. Thus, we aim to assess the benefit of CBM to treat youth anxiety. Further, we aim to test whether adding an adherence promotion (AP) component to the CBM intervention can improve outcomes, and whether CBM delivered both with and without the AP component is cost effective.

Methods: This is a 12-month randomized controlled trial (RCT) conducted within an existing healthcare system. Potentially eligible youth (ages 12 to 17) will be identified by reviewing the electronic health record (EHR) for clinical anxiety diagnoses, which are then confirmed via research interview. We aim to enroll 498 participants and randomize them 1:1:1 to one of three arms: Arm 1 is a Low-Ratio version of the CBM program (nearly identical to the other CBM versions, but minimally effective); Arm 2 is a High-Ratio "active" CBM program; and Arm 3 is the High-Ratio CBM program with an added AP component. Participants will complete assessments at baseline, 1-, 3-, 6- and 12-months post-baseline. Youth in all three arms will self-administer the CBM program at home and will be asked to complete twelve intervention sessions over a four-week period. Arm 3 participants (High-Ratio CBM + AP) will also receive up to four telephone calls from phone coaches during the intervention period to provide technical assistance, encouragement, and motivational enhancement to increase adherence. The primary clinical outcome will be anxiety remission at 6-month follow-up.

Discussion: This study protocol describes the method and design for an RCT to test whether self-administered CBM both with and without adherence promotion can be an effective at-home treatment for anxious youth.

Trial registration: ClinicalTrials.gov : NCT02156531, First Posted June 5, 2014.

Keywords: Adolescent; Anxiety disorder; Cognitive bias modification; Randomized controlled trial.

Conflict of interest statement

Dr. Amir was formerly a part owner of Cognitive Retraining Technologies, LLC (“CRT”), a company that marketed anxiety relief products. Dr. Amir’s ownership interest in CRT was extinguished on January 29, 2016, when CRT was acquired by another entity. Dr. Amir has an interest in royalty income generated by the marketing of anxiety relief products by this entity.

Figures

Fig. 1
Fig. 1
Participant Flow Diagram
Fig. 2
Fig. 2
Cognitive Bias Modification (CBM) program screenshots

Similar articles

See all similar articles

References

    1. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A) J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–989. doi: 10.1016/j.jaac.2010.05.017. - DOI - PMC - PubMed
    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. doi: 10.1001/archpsyc.62.6.617. - DOI - PMC - PubMed
    1. Marciniak MD, Lage MJ, Dunayevich E, Russell JM, Bowman L, Landbloom RP, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety. 2005;21(4):178–184. doi: 10.1002/da.20074. - DOI - PubMed
    1. Revicki DA, Travers K, Wyrwich KW, Svedsater H, Locklear J, Mattera MS, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140(2):103–112. doi: 10.1016/j.jad.2011.11.014. - DOI - PubMed
    1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327. - PMC - PubMed

Associated data

Feedback